[Development of delivery system of bisphosphonates for the treatment of osteoporosis]
Related Experiment Video
Updated: Jun 9, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
Published on: August 22, 2016
Hidemasa Katsumi1, Kosuke Kusamori, Toshiyasu Sakane
1Kyoto Pharmaceutical University, Kyoto, Japan. hkatsumi@mb.kyoto-phu.ac.jp
Abstract:
Bisphosphonates are carbon-substituted pyrophosphate (PCP) analogues that exhibit high affinity to hydroxylapatite and inhibit bone resorption after their administration. They are widely used as the first-choice drug for the treatment and prevention of bone diseases, including Paget's disease, hypercalcemia of malignancy, and osteoporosis. However, the oral bioavailability of bisphosphonates is quite low (1-2%). In addition, the oral administration of bisphosphonates has been associated with mucosal damage, including gastritis, gastric ulcer, and erosive esophagitis. Therefore, it is highly desirable to develop new delivery systems that improve their bioavailability and safety. In this review, recent challenges in the developments of novel delivery system of bisphosphonates are summarized. Then, future developments of delivery system of bisphosphonates are also discussed in order to improve their therapeutic efficacy and safety in the treatment of bone diseases.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Oral Drug Delivery Systems: Introduction
Oral Drug Delivery Systems: Delayed-Release Systems
Intrauterine Drug Delivery Systems
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices